182 related articles for article (PubMed ID: 18818739)
1. Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
Kumaran D; Rawat R; Ahmed SA; Swaminathan S
PLoS Pathog; 2008 Sep; 4(9):e1000165. PubMed ID: 18818739
[TBL] [Abstract][Full Text] [Related]
2. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S
Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088
[TBL] [Abstract][Full Text] [Related]
3. SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.
Agarwal R; Swaminathan S
J Biol Chem; 2008 Sep; 283(38):25944-51. PubMed ID: 18658150
[TBL] [Abstract][Full Text] [Related]
4. Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A.
Kumaran D; Rawat R; Ludivico ML; Ahmed SA; Swaminathan S
J Biol Chem; 2008 Jul; 283(27):18883-91. PubMed ID: 18434312
[TBL] [Abstract][Full Text] [Related]
5. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.
Zuniga JE; Schmidt JJ; Fenn T; Burnett JC; Araç D; Gussio R; Stafford RG; Badie SS; Bavari S; Brunger AT
Structure; 2008 Oct; 16(10):1588-97. PubMed ID: 18940613
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of substrate recognition by botulinum neurotoxin serotype A.
Chen S; Kim JP; Barbieri JT
J Biol Chem; 2007 Mar; 282(13):9621-9627. PubMed ID: 17244603
[TBL] [Abstract][Full Text] [Related]
7. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E.
Chen S; Barbieri JT
J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207
[TBL] [Abstract][Full Text] [Related]
8. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Kumar G; Kumaran D; Ahmed SA; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749
[TBL] [Abstract][Full Text] [Related]
9. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity.
Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT
Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519
[TBL] [Abstract][Full Text] [Related]
10. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
Chen S; Barbieri JT
J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
[TBL] [Abstract][Full Text] [Related]
11. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.
Ho M; Goh CH; Brothers MC; Wang S; Young RL; Ou Y; Lui JN; Kalafatis M; Lan X; Wolf AE; Rienstra CM; Wilson BA
Protein Sci; 2012 Mar; 21(3):318-26. PubMed ID: 22170566
[TBL] [Abstract][Full Text] [Related]
12. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite.
Schmidt JJ; Stafford RG; Bostian KA
FEBS Lett; 1998 Sep; 435(1):61-4. PubMed ID: 9755859
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
Agarwal R; Binz T; Swaminathan S
Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
[TBL] [Abstract][Full Text] [Related]
14. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
Hanson MA; Stevens RC
Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
[TBL] [Abstract][Full Text] [Related]
16. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
17. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
Ambrin G; Kumar R; Singh BR
Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity.
Segelke B; Knapp M; Kadkhodayan S; Balhorn R; Rupp B
Proc Natl Acad Sci U S A; 2004 May; 101(18):6888-93. PubMed ID: 15107500
[TBL] [Abstract][Full Text] [Related]
19. Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
Masuyer G; Zhang S; Barkho S; Shen Y; Henriksson L; Košenina S; Dong M; Stenmark P
Sci Rep; 2018 Mar; 8(1):4518. PubMed ID: 29540745
[TBL] [Abstract][Full Text] [Related]
20. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
